A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants.

Abstract

Background: Coronavirus disease (COVID-19) seriously endangers global public health. Pupingqinghua prescription (PPQH) is an herbal formula from traditional Chinese medicine used for treatment of SARS-CoV-2 infection. This study aims to evaluate the clinical efficacy and safety of PPQH in Chinese participants infected with the SARS-CoV-2 Omicron variant. Methods: A total of 873 SARS-CoV-2 (Omicron)-infected patients were included. Among them, the patients were divided into the PPQH group (653 cases) and LHQW group (220 cases) according to different medications. The effectiveness indicators (hematological indicators, Ct values of novel Coronavirus nucleic acid tests, and viral load-shedding time) and safety indicators (liver and kidney function and adverse events) were analyzed. Results: There was no significant difference in baseline characteristics between the PPQH group and the LHQW group, except the gender; After the treatment, the levels of IL-5, IL-6, IL-10, NK cells, and INF-α of the patients in the PPQH group showed a downward trend (p < 0.05); The viral load shedding time was 5.0 (5.0, 7.0) in the PPQH group and 5.0 (4.0, 7.0) in the LHQW group; both PPQH and LHQW can shorten the duration of symptoms of fever, cough, and sore throat. The re-positive rate of COVID-19 test was 1.5 % in the PPQH group and 2.3 % in the LHQW group. In terms of safety, the levels of γ-GTT decreased significantly (p < 0.01); gastrointestinal reaction was the primary adverse reaction, and the reaction rate was 4.7 % in the PPQH group and 9.5 % in the LHQW group. Conclusion: PPQH can shorten the length of hospital stay and improve clinical symptoms of patients with SARS-COV-2 (Omicron), and it also has a good safety profile.

• Authors: Yidan Dong, Wei Zhai, Bangjiang Fang, Chenyang Liu, Suyun Yuan, Youhua Wang, Qixiang Song, Hai Li, Bin Chen, Dan Cui, Jun Wang, Qiong Wu, Chang Zhou, Maolin Zhou, Shuchun Li, Xu Zhuang, Qingrong Xu, Yu Zheng, Yingen Wu, Junhua Zheng, Min Cao
• Journal: Frontiers in pharmacology (Front Pharmacol) Vol. 13 Pg. 988524 ( 2022) ISSN: 1663-9812 [Print] Switzerland
• PMID: 36278166 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Dong, Zhai, Fang, Liu, Yuan, Wang, Song, Li, Chen, Cui, Wang, Wu, Zhou, Zhou, Li, Zhuang, Xu, Zheng, Wu, Zheng and Cao.